IN THE CLAIMS

Please amend the claims as follows:

Claims 1-13 (Cancelled)

Claim 14 (Currently Amended): A compound represented by formula (1):



(1)

wherein:

A is a phenyl, naphthyl, dihydronaphthyl, indenyl, pyridyl, indolyl, isoindolyl, quinolyl or isoquinolyl group, any of which may be substituted;

B is a group of -CH=CH-, -C≡C-, -$(CH=CH)_2$-, -CH=CH-C≡C- or -C≡C-CH=CH-, or a divalent residue of benzene, pyridine, pyrimidine or pyrazine, any of which may be substituted; and

W is diazepine as shown in the following formula, where n is 3 and X is -CHY^1-CHY^2- or n is 2 and X is -CH_2-CHY^3-CH_2-



wherein Y^1, Y^2 and Y^3 are each independently selected from the group consisting of:

a hydrogen atom,

-$COOR^1$, wherein R^1 is a hydrogen atom or a lower alkyl group,

-$CON(R^2)R^3$, wherein R^2 and R^3 are each independently selected from the group consisting of a hydrogen atom, a hydroxyl group, and a lower alkyl group,

-$CH_2N(R^4)R^5$, wherein R^4 and R^5 are each independently a hydrogen atom or a lower alkyl group, or R^4 and R^5 may form, together with the adjacent nitrogen atom, a heterocyclic ring which may further have an oxygen, nitrogen or sulfur atom, and

-CH_2-S-R^6, wherein R^6 is a lower alkyl, phenyl or pyridyl group; ~~or~~

~~Y^1 and Y^2 may couple to each other to form an alkylene group which may be through an oxygen, nitrogen or sulfur atom,~~

or a salt thereof, or a hydrate or solvate thereof.

Claim 15 (Previously Presented): The compound according to Claim 14, wherein A is a phenyl, naphthyl, dihydronaphthyl, indenyl, pyridyl, indolyl, isoindolyl, quinolyl or isoquinolyl group any of which may have 1-3 substituents independently selected from the group consisting of a hydroxyl group, a halogen atom, a lower alkyl group which may be substituted by 1-3 halogen atoms, a lower alkoxy group, an amino group which may be substituted by one or two lower alkyl groups, and a lower alkylthio group.

Claim 16 (Previously Presented): A composition comprising the compound according to Claim 14 and a pharmaceutically acceptable carrier.

Claim 17 (Previously Presented): The composition according to Claim 16 in solid, semi-solid or liquid form.

Claim 18 (Previously Presented): The composition according to Claim 16 in the form of a tablet, pill, granule, soft capsule, hard capsule, powder, grain, trituration, emulsion, syrup, pellet or elixir.

Claim 19 (Previously Presented): The composition according to Claim 16 in the form of an injection, drop, infusion, ointment, lotion, tonic, spray, inhalation suspension, oil, emulsion or suppository.

Claim 20 (Previously Presented): The composition according to Claim 16, wherein said carrier comprises a surfactant, excipient, colorant, smell corrigent, preservative, stabilizer, buffer, suspension stabilizer, or isotonic agent.

Claim 21 (Previously Presented): The composition of Claim 16, wherein said compound is an acid-addition salt, a solvate or a hydrate.

Claim 22 (Previously Presented): A method for inhibiting the production of an IgE antibody comprising:

administering to a subject in need thereof an amount of the compound of Claim 14 suitable for inhibiting the production of IgE in said subject.

Claim 23 (Cancelled):

Claim 24 (Previously Presented): A method for treating an allergic immunological disease comprising administering an effective amount of the compound of Claim 14 to a subject in need thereof.

Claim 25 (Previously Presented): The method of Claim 24, wherein said allergic immunological disease is selected from the group consisting of asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease and contact dermatitis.

Claim 26 (Previously Presented): The method of Claim 24, wherein said effective amount ranges from 0.01-1,000 mg/kg/day.

Claim 27 (Previously Presented): The compound of Claim 14, wherein A is a phenyl or substituted phenyl.

Claim 28 (Currently Amended): The compound of Claim 14, wherein A is naphthyl or substituted naphthyl.

Claim 29 (Previously Presented): The compound of Claim 14, wherein A is dihydronaphthyl or substituted dihydronaphthyl.

Claim 30 (Previously Presented): The compound of Claim 14, wherein A is indenyl or substituted indenyl.

Claim 31 (Previously Presented): The compound of Claim 14, wherein A is pyridyl or substituted pyridyl.

Claim 32 (Previously Presented): The compound of Claim 14, wherein A is indolyl or substituted indolyl.

Claim 33 (Previously Presented): The compound of Claim 14, wherein A is isoindolyl or substituted isoindolyl.

Claim 34 (Previously Presented): The compound of Claim 14, wherein A is quinolyl or substituted quinolyl.

Claim 35 (Previously Presented): The compound of Claim 14, wherein A is isoquinolyl or substituted isoquinolyl.

Claim 36 (Previously Presented): The compound of Claim 14, wherein B is -CH=CH-, which may be substituted.

Claim 37 (Previously Presented): The compound of Claim 14, wherein B is -C≡C-.

Claim 38 (Previously Presented): The compound of Claim 14, wherein B is a group of $-(CH=CH)_2-$, which may be substituted.

Claim 39 (Previously Presented): The compound of Claim 14, wherein B is -CH=CH-C≡C-, which may be substituted.

Claim 40 (Previously Presented): The compound of Claim 14, wherein B is -C≡C-CH=CH-, which may be substituted.

Claim 41 (Previously Presented): The compound of Claim 14, wherein B is a divalent residue of benzene, which may be substituted.

Claim 42 (Previously Presented): The compound of Claim 14, wherein B is a divalent residue of pyridine, which may be substituted.

Claim 43 (Previously Presented): The compound of Claim 14, wherein B is a divalent residue of pyrimidine, which may be substituted.

Claim 44 (Previously Presented): The compound of Claim 14, wherein B is a divalent residue of pyrazine, which may be substituted.

Claim 45 (Previously Presented): The compound of Claim 14, wherein n is 3 and X is $-CHY^1-CHY^2-$.

Claim 46 (Previously Presented): The compound of Claim 14, wherein n is 2 and X is $-CH_2-CHY^3-CH_2-$.